(DCs) and macrophages. 4 Murine intestinal innate myeloid cells can be divided into 2 main subsets, CD103 + DCs and CX 3 CR1 + cells, and these subsets contribute to the maintenance of gut homeostasis by promoting and inhibiting effector T-cell responses. [5] [6] [7] [8] Murine CD103 + DCs in the small intestine, which differentiate through mechanisms involving the transcription factors Batf3, IRF4, and IRF8, [9] [10] [11] induce cytotoxic T lymphocytes, 12 CD4 +, and CD8 + T-cell proliferation, 13 and Foxp3 + regulatory T (Treg) cells through the production of retinoic acid and transforming growth factor (TGF-b). [14] [15] [16] Toll-like receptor (TLR) 5-activated murine CD103 + CD11c + DCs induce Th1/Th17 cell development. 17 In addition, flagellin-induced production of interleukin (IL)-23 by murine CD103 + DCs promotes IL-22 production by innate lymphoid cells, thereby inducing antimicrobial peptide expression in intestinal epithelial cells. 18 In the colon, murine CD103 + CD11b 2 DCs that are activated by Bifidobacterium breve produce IL-10 and IL-27, and thereby induce IL-10-producing type 1 regulatory T (Tr1) cells. 19 Several studies have identified human intestinal innate myeloid cell subsets that modulate the gut immune responses. Similar to murine CD103 + DCs, human CD103 + DCs induce the expression of gut homing receptors such as CCR9 and integrin a4b7 on T cells in the small intestine. 13 In addition, human CD103 + Sirpa 2 DCs, which are the equivalent of murine CD103 + CD11b 2 DCs, promote T helper (Th)17 cell differentiation. 20, 21 Moreover, human CD103 + Sirpa + DCs, which are identical to murine CD103 + CD11b + DCs, generate Foxp3 + Treg cells and Th17 cells. 20 Furthermore, human CD103 + Sirpa + DCs have enhanced phagocytic activity in the colon versus the ileum. 22 However, the functional properties of T-cell differentiation in colonic CD103 + DCs remain poorly understood, and it is unclear whether these cells are implicated in the pathogenesis of IBD.
This study found that Lin 2 CD45 + HLA-DR high CD103 + DCs from the normal human colon induced the differentiation of naive T cells into Foxp3 + Treg cells but not into Th1 and Th17 cells. In contrast, CD103 + DCs from the colons of patients with UC exhibited markedly increased Th1/Th2/Th17-inducing activity that was accompanied by higher expression of IL6, IL23A, IL12p35, and TNF, whereas decreased Foxp3 + Treg cellinducing activity.
MATERIALS AND METHODS

Intestinal Tissue Samples
Normal intestinal mucosa samples (n ¼ 24) were obtained from patients with colorectal cancer. 23 The samples were taken from macroscopically and microscopically intact sites as described previously. 24, 25 Samples of noninflamed and inflamed intestinal mucosa (n ¼ 13) were also obtained from the surgically resected specimens of patients with UC (Table 1) . These patients were diagnosed according to their clinical, radiological, endoscopic, and histopathological findings, based on established criteria. 26 This study was approved by the Ethics Committee of the Osaka University School of Medicine. Written informed consent was obtained from all patients for the use of their samples and data.
Isolation of Lamina Propria Cells
Human intestinal lamina propria cells (LPCs) were isolated using a protocol described previously, with slight modifications. 24 In brief, intestinal mucosa was washed in phosphate-buffered saline (PBS) to remove feces and then placed in Hank's balanced salt solution (HBSS) containing 5 mM ethylenediaminetetracetic acid (EDTA) and incubated for 3 minutes with shaking. After washing with PBS, the underlying muscular layers and fat were removed, and the remaining tissue was cut into small pieces. The tissue was incubated in Roswell Park Memorial Institute 1640 medium containing 4% fetal bovine serum (FBS), 0.13 Wünsch units/mL Liberase (Roche Life Science, Mannheim, Germany), and 80 U/mL DNase I (Sigma-Aldrich, St. Louis, MO) for 2 · 60 minutes in a 378C shaking water bath. 10 The medium and enzymes were changed between 2 rounds of 60-minute incubations. The digested tissues were then resuspended in HBSS containing 5 mM EDTA and passed first through a 100-mm cell strainer and then through a 40-mm cell strainer. The isolated cells were washed with PBS, resuspended in 5 mL of 20% Percoll (GE Healthcare, Little Chalfont, England), and overlaid on 2.5 mL of 40% Percoll in a 15-mL tube. Percoll gradient separation was performed by centrifugation at 500g for 30 minutes at 48C. The LPCs were collected at the Percoll gradient interface and washed with PBS containing 2% FBS.
Flow Cytometry and Data Analysis
Flow cytometry analysis was performed using a FACSCanto II (BD Biosciences, Franklin Lakes, New Jersey). LPCs were purified using a FACSAria (BD Biosciences). The instrument settings were adjusted for 6-color stained samples. Data were analyzed with FlowJo software (Tree Star, Ashland, OR). 
Antibodies
The following antibodies were purchased from BioLegend, San Diego, CA: antihuman CD1c 
Quantitative Real-time Polymerase Chain Reaction
Total RNA was purified using the RNeasy Mini kit (Qiagen, Manchester, United Kingdom), and complementary DNAs were synthesized using the High-Capacity RNA-to-cDNA Kit (Thermo Fisher Scientific, Waltham, MA). Quantitative realtime polymerase chain reaction was performed on a Step One Plus system Real-Time PCR System (Applied Biosystems, Foster City, CA) using the GoTaq qPCR Master Mix (Promega, Madison, WI). The amplification conditions were as follows: 508C (2 min), 958C (10 min), and 50 cycles at 958C (15 sec) and 608C (60 sec). All data were normalized to the expression of the GAPDH gene, which encodes glyceraldehyde 3-phosphate dehydrogenase. The primer sets are shown in Table 1 
Morphological Analysis
Isolated LPC subsets were spread on glass slides, air-dried, fixed with methanol, and stained with May-Grünwald-Giemsa. Images of the May-Grünwald-Giemsa staining were taken with a BZ-X710 microscope system (Keyence, Osaka, Japan).
T-Cell Differentiation Assay
Naive CD4 + T cells were isolated using a FACSAria as CD45RA + CD4 + T cells from the peripheral blood mononuclear cells of healthy volunteers. Isolated allogeneic naive CD4 + T cells were cultured with LPC subsets from the colon at a 5:1 ratio in the presence of 10 U/mL IL-2 (Roche Life Science) and 2% human serum on a plate coated with antihuman CD3 (Corning, New York). After 7 days, the cells were analyzed for Foxp3 expression using a Human Foxp3 Staining Kit (eBioscience) according to the manufacturer's protocol. The concentrations of IL-4, IL-5, IL-13, IL-17, and IFN-g in the culture supernatants were measured using a Cytometric Bead Array (CBA) kit (BD Biosciences).
Statistical Analysis
The assumption of normality was examined with the Shapiro-Wilk test and D'Agostino & Pearson test, and all the data passed the normality test. The statistical significance of differences between 2 groups was calculated by the Student's t test. When more than 2 groups were compared, 1-way analysis of variance was used followed by Holm-Sidak's multiple comparisons test to determine the statistical significance of the differences. Statistical analyses were performed using GraphPad Prism version 6.00 (Graphpad Software, San Diego, CA). Differences with P , 0.05 were considered to be significant. (Fig. 1A, B) , as described previously. 21 The frequency of CD103 + cells (1.7% 6 0.2%) was significantly lower than the frequency of CD14 + cells (29.4% 6 2.3%) (P , 0.0001), and it was also lower than the frequency of CD103 + cells in the small intestine (5.9% 6 0.3%) (P , 0.0001) (see Fig. 2A , Supplementary Digital Content 3, http://links.lww.com/IBD/B565). Similar to CD103 + cells from the human small intestine, 20 CD103 + cells from the human colon can be divided into 2 subsets: CD103 + Sirpa + cells (38.2% 6 2.1%) and CD103 + Sirpa 2 cells (61.8% 6 2.1%) (see Fig. 2B , Supplementary Digital Content 3, http://links.lww.com/IBD/B565). CD103 + cells from the human colon had DC-like morphology with some dendrites, whereas CD14 + cells had macrophage-like morphology with some cytoplasmic vacuoles (Fig. 1C) . We further analyzed the surface expression of several markers on CD103 + cells and CD14 + cells from the colon (Fig. 1D) . CD103 + cells expressed CD11c and several DC markers, including CD1c and CD141, but they did not have macrophage markers such as CD64 and CD206 or mature DC markers such as CD80, CD83, and CD86, identifying CD103 + cells in NC as CD103 + CD11c + CD1c +/2 CD141 +/2 cells. In contrast, CD14 + cells showed high expression of CD64 and CD206, as reported previously, [27] [28] [29] characterizing as CD14 + CD64 + CD206 + CD86 + CD11c +/2 CD83 +/2 cells.
RESULTS
Characterization of Lin
To further confirm that CD103 + cells in the human colon are the equivalent of murine intestinal CD103 + DCs, we analyzed the messenger RNA (mRNA) expression of the murine CD103 + DC-related transcription factors BATF3, IRF8, and IRF4 (Fig.  1E ). 9-11 CD103 + cells isolated from NC showed higher expression of BATF3 (P , 0.01), IRF8 (P , 0.01), and IRF4 (P , 0.0001) than CD14 + cells. Thus, CD103 + cells that were isolated from normal human colon tissue had phenotypes that were similar to those of CD103 + DCs in the normal human small intestine, which are considered comparable to murine CD103 + cells. 20 Therefore, CD103 + cells in the human colon are hereafter called CD103 + DCs.
Comparison of the mRNA Expression Patterns in CD103 + DCs Versus CD14 + Cells in NC We next examined the TLR mRNA expression patterns using quantitative real-time polymerase chain reaction in CD103 + DCs and CD14 + cells isolated from NC ( Fig. 2A) . CD14 + cells expressed significantly higher levels of TLR2 (P , 0.01), TLR4 (P , 0.001), and TLR5 (P , 0.05) than CD103 + DCs. The expression levels of TLR3, TLR7, and TLR9 in CD103 + DCs were almost identical to those in CD14 + cells. We further evaluated the expression of proinflammatory and antiinflammatory cytokines in the 2 subsets of cells (Fig. 2B) . CD103 + DCs showed lower expression of proinflammatory cytokines, such as IL6 (P , 0.0001), IL23A (P , 0.0001), and TNF (P , 0.0001), than did CD14 + cells. However, the expression levels of IL12p35 and anti-inflammatory cytokines, including IL10 and TGFB, in CD103 + DCs were similar to the levels in CD14 + cells. Overall, compared with CD14 + cells, CD103 + DCs in the normal human colon showed lower expression of costimulatory molecules (CD83 and CD86) and proinflammatory cytokines (IL6, IL23A, and TNF). Thus, human colon CD103 + DCs seem to possess an anti-inflammatory properties, rather than inflammatory properties.
Functional Characterization of the Roles of CD103 + DCs and CD14 + Cells from NC in T-Cell Differentiation
Because previous reports have demonstrated that CD103 + DCs induce Foxp3 + Treg cells in human and murine small intestines, 13, 20, 22 we investigated whether CD103 + DCs in the human colon could induce Foxp3 + Treg cells. Allogenic naive CD4 + T cells were cultured with CD103 + DCs and CD14 + cells isolated from NC. After 7 days of coculture, Foxp3 expression in CD4 + T cells was analyzed and found to be induced by coculture with CD103 + DCs (10.8% 6 1.5%) but not CD14 + cells (1.3% 6 0.6%) (Fig. 3A) . In accordance with this finding, CD4 + T cells that were cocultured with CD103 + DCs showed the highest mean fluorescence intensity for Foxp3 (P , 0.001) (Fig. 3A) . In this context, almost all Foxp3 + Treg cells induced by CD103 + DCs in vitro expressed another Treg marker, CD25 (data not shown).
We next analyzed the Th1-and Th17-inducing activity of CD103 + DCs and CD14 + cells. As before, allogenic CD4 + naive T cells were cocultured with CD103 + DCs and CD14 + cells, and the concentration of IL-17 and IFN-g in the culture supernatants was analyzed by CBA (Fig. 3B, C) . We found that CD14 + cells induced IL-17-producing CD4 + T cells, as reported previously, 24 whereas CD103 + DCs did not. Neither CD103 + DCs nor CD14 + cells induced IFN-g-producing CD4 + T cells. These findings indicated that human CD103 + DCs in NC might be tolerogenic CD103 + DCs with the ability to generate Foxp3 + Treg cells.
Induction of Effector T-Cell Differentiation by CD103 + DCs from the Colons of Patients with UC
Although several studies have analyzed intestinal CD103 + DCs in patients with IBD, 13, 21, 30, 31 few have investigated whether CD103 + DCs in patients with IBD can induce Foxp3 + Treg, Th1, or Th17 cells. Therefore, we characterized CD103 + DCs from the colons of patients with UC. In patients with UC, the frequency of CD103 + DCs was markedly reduced in both noninflamed (UCn) and inflamed (UCi) sites of the colon (P , 0.0001) (Fig.  4A) , as shown previously. 21 In addition, the frequency of CD103 + Sirpa + DCs was significantly decreased even at the UCn site compared with NC (P , 0.0001) (Fig. 4B) . CD103 + Sirpa + DCs, but not CD103 + Sirpa 2 DCs, have been reported to generate Foxp3 + Treg cells in the human small intestine. 20 Therefore, we evaluated whether the Treg cell-inducing ability of CD103 + DCs is altered in patients with UC compared with those in NC. Allogenic naive CD4 + T cells were cultured with CD103 + DCs isolated from NC, UCn, and UCi for 7 days, and then Foxp3 expression in CD4 + T cells was analyzed (Fig. 4C) . CD103 + DCs from NC induced Foxp3 + Treg cells (8.0% 6 0.9%), as shown in Figure 3A . However, CD103 + DCs from UCn and UCi sites did not induce Foxp3 + Treg cells. Accordingly, in CD4 + T cells that were cocultured with CD103 + DCs from patients with UC, the mean fluorescence intensity of Foxp3 was significantly lower than that induced by CD103 + DCs from NC (P , 0.0001) (Fig. 4C) . Because Treg cell-inducing capacity of CD103 + DCs from patients with UC was impaired, we further investigated the activity of CD103 + DCs in patients with UC to induce the differentiation of naive T cells into Th1 and Th17 cells by comparing with those in NC. The culture supernatants from cocultures of allogenic naive T cells with CD103 + DCs isolated from NC, UCn, and UCi were analyzed by CBA to determine the production of IL-17 and IFN-g (Fig. 5A, B) . CD4 + T cells cultured with CD103 + DCs from UCn and UCi, but not from NC, produced high amounts of IL-17 (P , 0.0001) and IFN-g (P , 0.0001). CD103 + DCs from UCi induced more IL-17-producing CD4 + T cells than those from UCn, indicating that CD103 + DCs in patients with UC possess enhanced activity to induce Th1 and Th17 cells compared with those in NC. In accordance with the fact that increased number of Th2 cells was found in patients with UC, 32, 33 intestinal DCs including CD103 + DCs from patients with UC have shown to induce Th2 cell differentiation. 34 Therefore, we further analyzed whether CD103 + DCs in patients with UC could facilitate Th2 cell development. Allogenic naive CD4 + T cells were cultured with CD103 + DCs from NC, UCn, and UCi and analyzed for production of Th2-related cytokines, such as IL-4, IL-5, and IL-13 ( Fig. 5C-E) . Coculture of CD103 + DCs from UCn and UCi induced increased CD4 + T-cell production of IL-13 (P , 0.0001), but not IL-4 and IL-5, compared with that from NC, indicating that CD103 + DCs might contribute to accumulation of Th2 cells as well as Th1 and Th17 cells. Data represent the mean 6 SEM of 4 experiments using 4 independent donor-derived samples. not significant. ***P , 0.001, ****P , 0.0001. B and C, IL-17 and IFN-g production by CD4 + T cells that were cultured with the indicated cells. Data represent the mean 6 SEM of 4 experiments of 4 independent donor-derived samples. ns, not significant. ****P , 0.0001.
To determine how CD103 + DCs from patients with UC acquired the ability to facilitate the differentiation of effector T cells, we compared the expression of proinflammatory cytokines and anti-inflammatory cytokines, which are responsible for the differentiation or maintenance of effector T cells (IL6, IL23A, IL12p35, and TNF) and Foxp3 + Treg cells (IL10 and TGFB), between CD103 + DCs isolated from NC, UCn, and UCi (Fig. 6 ). There were no differences in the expression of anti-inflammatory cytokines such as IL10 and TGFB in CD103 + DCs from NC, UCn, and UCi. In contrast, CD103 + DCs from UCn exhibited partially increased expression of proinflammatory cytokines, including IL6 (P , 0.05), IL23A, IL12p35, and TNF, compared with CD103 + DCs from NC. Furthermore, CD103 + DCs from UCi sites expressed the highest levels of IL6 (P , 0.0001), IL23A (P , 0.05), IL12p35 (P , 0.05), and TNF (P , 0.05). Thus, in accordance with the observed increased effector T cellinducing activity, CD103 + DCs from patients with UC showed inflammatory phenotypes in terms of the effector T cell-inducing proinflammatory cytokine expression.
DISCUSSION
In this study, we characterized colonic CD103 + DCs in patients with UC. The number of CD103 + DCs was greatly reduced in the colons of patients with UC. Furthermore, Treg cell-inducing ability was impaired in CD103 + DCs in patients with UC, and this subset strongly induced the development of Th1, Th2, and Th17 cells, which was associated with the enhanced expression of proinflammatory cytokines. Thus, the inflammatory phenotype of CD103 + DCs in the colon might be involved in the pathogenesis of UC.
Monoclonal antibodies targeting integrins are emerging as new treatment option in IBD. 35 b7 integrin forms the heterodimer with CD103 (aE integrin) and a4. The monoclonal antibody targeting a4b7 has been approved for the treatment of patients with IBD. 36 Etrolizumab, which is a humanized monoclonal antibody specific for the b7 integrin subunit, is currently under evaluation in phase 3 trial. 37, 38 Anti-b7 provides a dual approach mechanism that involves both inhibition of lymphocytes trafficking to the intestinal mucosa and inhibition of retention of lymphocytes in the intraepithelial compartment, which may provide improved efficacy over currently available therapies. 35 A recent study demonstrated that etrolizumab surrogate antibody is more potent than vedolizumab, a monoclonal antibody to a4b7, in reducing accumulation of human CD8 + T cells and CD4 + Th9 cells in the inflamed gut, using an in vivo model for IBD T-cell trafficking in humanized model. 39 In patients with UC, it was reported that aEb7 integrin expression on colonic CD4 + T cells was associated with increased production of proinflammatory Th1, Th17, and Th1/Th17 cytokines. 40 In this study, CD103 + DCs in patients with UC had an ability to drive Th1/Th2/Th17 cell responses. Therefore, the efficacy of etrolizumab might be explained by elimination of colitogenic CD103 + DCs and blockade of lymphocytes recruitment. Retinoic acid produced by CD103 + DCs is important for the induction of Foxp3 + Treg cells in the murine small intestine. 14 In the human small intestine, CD103 + Sirpa + DCs that generate Foxp3 + Treg cells show high retinaldehyde-specific dehydrogenase (RALDH) activity. 20, 22 Recent studies demonstrated that the number of RALDH-expressing CD141 + DCs and CD1c + DCs was markedly diminished in the colon of patients with UC. 21, 41 These subsets contain CD103 + DCs, as shown in Figure 1D and in previous studies. 10, 20, 42 Therefore, it is possible that a reduction in the number of retinoic acid-producing CD103 + Sirpa + DCs may be linked to the impaired Foxp3 + Treg cell-inducing activity shown by the CD103 + DC subset in patients with UC.
Previous studies have reported that intestinal epithelial cells suppress the production of IL-23 and IL-12 by CD103 + DCs. 1 Lamina propria mononuclear cells in patients with UC produce higher levels of the Th2 cytokine IL-13, which facilitates the apoptosis of intestinal epithelial cells in patients with UC. 43 Thus, the presence of fewer epithelial cells producing CD103 + DC modulators may be linked to enhanced expression of proinflammatory cytokines in CD103 + DCs from the colons of patients with UC. CD103 + DCs in NC did not express mature DC markers including CD80, CD83, and CD86. It has been reported that DC maturation is inhibited by ligation of E-cadherin. 44 Therefore, epithelial cells may restrict CD103 + DC maturation by the interaction through the E-cadherin/CD103 axis.
Human intestinal CD103 2 CD11c + CCR2 + DCs are equivalent to murine CD103 2 CCR2 + DCs with the ability to induce Th17 cells. 45 We observed that the frequency of CD103 2 CD11c + DCs among Lin 2 CD45 + HLA 2 DR high cells was increased in the colons of patients with UC (75.2% 6 7.2%) compared with those in NC (58.7% 6 1.7%) (our unpublished observation). However, it remains unclear whether the Th17-inducing activity of CD103 2 CD11c + DCs is accelerated in patients with UC. Therefore, a detailed analysis of CD103 2 and CD103 + DCs in patients with UC would help advance our understanding of gut homeostasis by human intestinal innate myeloid cells.
Compared with CD14 + cells, CD103 + DCs from NC produced lower amounts of proinflammatory cytokines accompanied with the reduced expression of TLR2/4/5. CD14 + cells might produce proinflammatory cytokines through the TLR-dependent recognition of commensal bacteria. 24, 29, 46 The expression of TLR2/4 is shown to be enhanced in intestinal DCs from patients with UC. 34 Therefore, it would be an important issue to analyze whether the enhanced production of cytokines in CD103 + DCs from patients with UC correlates with the increased expression of TLRs.
In accordance with previous studies showing the reduced number of CD103 + DCs in patients with active UC and Crohn's disease, 21, 30, 34 the number of CD103 + DCs was markedly reduced in both UCn and UCi in the current study. In addition, the ability of these cells to induce Foxp3 + Treg cells was greatly decreased in patients with UC. In the future, analysis of more samples from patients with UC will be needed to analyze the underlying mechanism for the maintenance of CD103 + DCs because these cells might offer a novel therapeutic target for IBD.
In conclusion, this study found that CD103 + DCs in patients with UC showed an impaired ability to generate Foxp3 + Treg cells but had acquired a potent ability to drive Th1/Th2/Th17 cell responses. Identifying the detailed and precise mechanisms by which tolerogenic CD103 + DCs are altered into colitogenic CD103 + DCs may help the development of a novel immunomodulatory therapy for UC.
